Craft
  • Home
  •  / Aprea Therapeutics
Aprea Therapeutics

Aprea Therapeutics

Pre-Clinical Phase Products

1

Sep, 2019

Market Capitalization

$16.5 M

2022-09-21

Aprea Therapeutics Summary

Company summary

Overview
Aprea Therapeutics is a pharmaceutical development company that is engaged in the discovery and development of anticancer compounds targeting tumour suppressor proteins. The company offers p53, a tumor suppressor protein that responds to various forms of cellular stresses and activates transcription of genes that induce cell cycle arrest or apoptosis; APR-246 that reactivates mutant and defective native p53, leading to tumor cell death; and APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
Type
Public
Founded
2003
HQ
Solna, SE | view all locations
Website
https://www.aprea.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Scott M. Rocklage, Chairman

    • Christian Schade, Chairman, Chief Executive Officer

      • Scott M. Coiante, Senior Vice President and Chief Financial Officer

        • Guido Magni, Director

          Operating MetricsView all

          Pre-Clinical Phase Products

          1

          Sep, 2019

          Preclinical Phase Products (Frontline and Relapsed / Refractory)

          1

          Sep, 2019

          Phase II Trials Products (Post-Transplant Maintenance)

          1

          Sep, 2019

          LocationsView all

          2 locations detected

          • Solna, Stockholms län HQ

            Sweden

            Olof af Acrels väg 4-6

          • Boston, MA

            United States

            535 Boylston St

          Aprea Therapeutics Financials

          Summary financials

          Net income (Q2, 2022)
          ($98.3M)
          Cash (Q2, 2022)
          $39.1M
          Enterprise value
          ($22.2M)

          Footer menu